Flexion Therapeutics on Friday earned Food and Drug Administration approval for Zilretta, an extended-release treatment for osteoarthritis knee pain. Here are three things to know. 1. Zilretta is ...
Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc. for $8.00 per share in cash plus an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback